Literature DB >> 27299736

The "Cyclopropyl Fragment" is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules.

Tanaji T Talele1.   

Abstract

Recently, there has been an increasing use of the cyclopropyl ring in drug development to transition drug candidates from the preclinical to clinical stage. Important features of the cyclopropane ring are, the (1) coplanarity of the three carbon atoms, (2) relatively shorter (1.51 Å) C-C bonds, (3) enhanced π-character of C-C bonds, and (4) C-H bonds are shorter and stronger than those in alkanes. The present review will focus on the contributions that a cyclopropyl ring makes to the properties of drugs containing it. Consequently, the cyclopropyl ring addresses multiple roadblocks that can occur during drug discovery such as (a) enhancing potency, (b) reducing off-target effects, (c) increasing metabolic stability, (d) increasing brain permeability, (e) decreasing plasma clearance, (f) contributing to an entropically more favorable binding to the receptor, (g) conformational restriction of peptides/peptidomimetics to prevent proteolytic hydrolysis, and (h) altering drug pK to reduce its P-glycoprotein efflux ratio.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27299736     DOI: 10.1021/acs.jmedchem.6b00472

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  84 in total

1.  Origin of high stereocontrol in olefin cyclopropanation catalyzed by an engineered carbene transferase.

Authors:  Antonio Tinoco; Yang Wei; John-Paul Bacik; Daniela M Carminati; Eric J Moore; Nozomi Ando; Yong Zhang; Rudi Fasan
Journal:  ACS Catal       Date:  2018-12-28       Impact factor: 13.084

2.  Radical-Polar Crossover Annulation: A Platform for Accessing Polycyclic Cyclopropanes.

Authors:  John A Milligan; Kevin L Burns; Anthony V Le; Viktor C Polites; Zheng-Jun Wang; Gary A Molander; Christopher B Kelly
Journal:  Adv Synth Catal       Date:  2019-11-08       Impact factor: 5.837

3.  Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D3 Receptor (D3R).

Authors:  Vivek Kumar; Amy E Moritz; Thomas M Keck; Alessandro Bonifazi; Michael P Ellenberger; Christopher D Sibley; R Benjamin Free; Lei Shi; J Robert Lane; David R Sibley; Amy Hauck Newman
Journal:  J Med Chem       Date:  2017-02-10       Impact factor: 7.446

4.  Stereoselective Cyclopropanation of Electron-Deficient Olefins with a Cofactor Redesigned Carbene Transferase Featuring Radical Reactivity.

Authors:  Daniela M Carminati; Rudi Fasan
Journal:  ACS Catal       Date:  2019-09-05       Impact factor: 13.084

5.  Strategies for the expression and characterization of artificial myoglobin-based carbene transferases.

Authors:  Daniela M Carminati; Eric J Moore; Rudi Fasan
Journal:  Methods Enzymol       Date:  2020-08-06       Impact factor: 1.600

Review 6.  Kinetics, mechanism, and inhibition of monoamine oxidase.

Authors:  Rona R Ramsay; Alen Albreht
Journal:  J Neural Transm (Vienna)       Date:  2018-03-07       Impact factor: 3.575

7.  Radical/Polar Annulation Reactions (RPARs) Enable the Modular Construction of Cyclopropanes.

Authors:  John A Milligan; James P Phelan; Viktor C Polites; Christopher B Kelly; Gary A Molander
Journal:  Org Lett       Date:  2018-10-15       Impact factor: 6.005

8.  Chemoselective Cyclopropanation over Carbene Y-H Insertion Catalyzed by an Engineered Carbene Transferase.

Authors:  Eric J Moore; Viktoria Steck; Priyanka Bajaj; Rudi Fasan
Journal:  J Org Chem       Date:  2018-07-06       Impact factor: 4.354

9.  Cobalt-Catalyzed Reductive Dimethylcyclopropanation of 1,3-Dienes.

Authors:  Jacob Werth; Christopher Uyeda
Journal:  Angew Chem Int Ed Engl       Date:  2018-09-25       Impact factor: 15.336

10.  Cobalt Catalyzed Reductive Spirocyclopropanation Reactions.

Authors:  Jacob Werth; Kristen Berger; Christopher Uyeda
Journal:  Adv Synth Catal       Date:  2019-11-06       Impact factor: 5.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.